BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 25510351)

  • 1. L1CAM is expressed in triple-negative breast cancers and is inversely correlated with androgen receptor.
    Doberstein K; Milde-Langosch K; Bretz NP; Schirmer U; Harari A; Witzel I; Ben-Arie A; Hubalek M; Müller-Holzner E; Reinold S; Zeimet AG; Altevogt P; Fogel M
    BMC Cancer; 2014 Dec; 14():958. PubMed ID: 25510351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
    Choi JE; Kang SH; Lee SJ; Bae YK
    Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
    Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
    Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
    Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
    BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A targetable androgen receptor-positive breast cancer subtype hidden among the triple-negative cancers.
    Safarpour D; Tavassoli FA
    Arch Pathol Lab Med; 2015 May; 139(5):612-7. PubMed ID: 25310144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor expression is a favorable prognostic factor in triple-negative breast cancers.
    Zuo T; Wilson P; Cicek AF; Harigopal M
    Hum Pathol; 2018 Oct; 80():239-245. PubMed ID: 29902579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers.
    Ward AK; Mellor P; Smith SE; Kendall S; Just NA; Vizeacoumar FS; Sarker S; Phillips Z; Alvi R; Saxena A; Vizeacoumar FJ; Carlsen SA; Anderson DH
    Breast Cancer Res; 2016 Jan; 18(1):12. PubMed ID: 26810754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen receptor expression shows distinctive significance in ER positive and negative breast cancers.
    Tsang JY; Ni YB; Chan SK; Shao MM; Law BK; Tan PH; Tse GM
    Ann Surg Oncol; 2014 Jul; 21(7):2218-28. PubMed ID: 24639191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the androgen receptor in triple-negative breast cancer.
    Rampurwala M; Wisinski KB; O'Regan R
    Clin Adv Hematol Oncol; 2016 Mar; 14(3):186-93. PubMed ID: 27058032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of L1CAM is associated with tumor progression and prognosis via ERK signaling in gastric cancer.
    Ito T; Yamada S; Tanaka C; Ito S; Murai T; Kobayashi D; Fujii T; Nakayama G; Sugimoto H; Koike M; Nomoto S; Fujiwara M; Kodera Y
    Ann Surg Oncol; 2014 Feb; 21(2):560-8. PubMed ID: 24046108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L1CAM expression in endometrial carcinomas is regulated by usage of two different promoter regions.
    Pfeifer M; Schirmer U; Geismann C; Schäfer H; Sebens S; Altevogt P
    BMC Mol Biol; 2010 Aug; 11():64. PubMed ID: 20799950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. L1 cell adhesion molecule promotes tumorigenicity and metastatic potential in non-small cell lung cancer.
    Hai J; Zhu CQ; Bandarchi B; Wang YH; Navab R; Shepherd FA; Jurisica I; Tsao MS
    Clin Cancer Res; 2012 Apr; 18(7):1914-24. PubMed ID: 22307136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of l1 cell adhesion molecule and morphologic features at the invasive front of colorectal cancer.
    Kajiwara Y; Ueno H; Hashiguchi Y; Shinto E; Shimazaki H; Mochizuki H; Hase K
    Am J Clin Pathol; 2011 Jul; 136(1):138-44. PubMed ID: 21685041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of L1 cell adhesion molecule correlates with aggressive tumor progression of patients with breast cancer and promotes motility of breast cancer cells.
    Zhang J; Yang F; Ding Y; Zhen L; Han X; Jiao F; Tang J
    Int J Clin Exp Pathol; 2015; 8(8):9240-7. PubMed ID: 26464672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low prognostic implication of fibroblast growth factor family activation in triple-negative breast cancer subsets.
    Lee HJ; Seo AN; Park SY; Kim JY; Park JY; Yu JH; Ahn JH; Gong G
    Ann Surg Oncol; 2014 May; 21(5):1561-8. PubMed ID: 24385208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Androgen Receptor Promotes Cellular Proliferation by Suppression of G-Protein Coupled Estrogen Receptor Signaling in Triple-Negative Breast Cancer.
    Shen Y; Yang F; Zhang W; Song W; Liu Y; Guan X
    Cell Physiol Biochem; 2017; 43(5):2047-2061. PubMed ID: 29059676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholesterol synthesis inhibitor RO 48-8071 suppresses transcriptional activity of human estrogen and androgen receptor.
    Mafuvadze B; Liang Y; Hyder SM
    Oncol Rep; 2014 Oct; 32(4):1727-33. PubMed ID: 25051231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic regulation of L1CAM in endometrial carcinoma: comparison to cancer-testis (CT-X) antigens.
    Schirmer U; Fiegl H; Pfeifer M; Zeimet AG; Müller-Holzner E; Bode PK; Tischler V; Altevogt P
    BMC Cancer; 2013 Mar; 13():156. PubMed ID: 23530769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of increased osteopontin and splice variant-c mRNA expression with HER2 and triple-negative/basal-like breast carcinomas subtypes and recurrence.
    Ortiz-Martínez F; Perez-Balaguer A; Ciprián D; Andrés L; Ponce J; Adrover E; Sánchez-Payá J; Aranda FI; Lerma E; Peiró G
    Hum Pathol; 2014 Mar; 45(3):504-12. PubMed ID: 24440093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.